TABLE 2.
Comparison of baseline characteristics by the development of eGFR decline during follow‐up
| Variables | Nondecline in eGFR (n = 129) | Decline in eGFR (n = 14) | p‐Value |
|---|---|---|---|
| Age, years | 75 (69.5‐78) | 78 (66.5‐82.5) | .078 |
| Women, n (%) | 50 (38.8) | 5 (35.7) | .82 |
| Follow‐up, month | 13 (11.5‐14) | 12 (11.75‐12.25) | .14 |
| eGFR, ml/min/1.73 m2 | 62.3 (45.4‐72.1) | 35.65 (24.2‐56.2) | <.01 |
| SBP, mmHg | 131 (124‐140) | 150.5 (137‐158) | <.01 |
| UPCR, g/g Cr | 0.06 (0.04‐0.13) | 0.13 (0.035‐1.49) | .52 |
| UACR, mg/g Cr | 20.95 (9.3‐68.6) | 263.3 (13.3‐1789.9) | .013 |
| Urinary vanin‐1, ng/mg Cr | 0 (0‐1.45) | 6.34 (2.44‐13.2) | <.01 |
All results are presented as median (interquartile range) or n (%).
Abbreviations: Cr, creatinine; eGFR, estimated glomerular filtration rate; SBP, systolic blood pressure; UACR, urinary albumin‐to‐creatinine ratio; UPCR, urinary protein‐to‐creatinine ratio.